Innovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control

J Control Release. 2022 Aug:348:357-369. doi: 10.1016/j.jconrel.2022.05.033. Epub 2022 Jun 9.

Abstract

The recent rapid progress in the area of drug delivery systems (DDS) has opened a new era in medicine with a strong linkage to understanding the molecular mechanisms associated with cancer survival. In this review, we summarize new cancer strategies that have recently been developed based on our DDS technology. Cancer immunotherapy will be improved based on the concept of the cancer immunity cycle, which focuses on dynamic interactions between various types of cancer and immune cells in our body. The new technology of genome editing will also be discussed with reference to how these new DDS technologies can be used to introduce therapeutic cargoes into our body. Lastly, a new organelle, mitochondria will be the focus of creating a new cancer treatment strategy by a MITO-Porter which can deliver macromolecules directly to mitochondria of cancer cells via a membrane fusion approach and the impact of controlled intracellular trafficking will be discussed.

Keywords: Adjuvant delivery; Genome editing; Innate immunity; Lipid nanoparticles; MITO-porter; Mitochondrial delivery.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Delivery Systems
  • Gene Editing
  • Humans
  • Liposomes
  • Nanomedicine*
  • Neoplasms* / therapy

Substances

  • Liposomes